Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Innovate or perish? Helping developing countries fight neglected diseases

26.10.2005


For the health challenges facing developing countries, the numbers alone are staggering. Every day, 40,000 people --enough to fill a sports stadium -- die from preventable infectious diseases and malnutrition. Entire generations of human potential are perishing.



Given the scope of these challenges, is there a way for developing countries to solve health disparities and bootstrap these efforts into economic growth? In an article published recently in the journal Science, Biodesign Institute researchers Rich Mahoney and Anatole Krattiger, along with a large, international group of collaborators, have outlined new strategies to help developing countries address neglected diseases.

"Many developing countries are attempting to solve the health problems facing their own populations, and they are rapidly increasing investments in science and technology infrastructure," said Mahoney.


In addition to their research roles in the institute’s Center for Infectious Diseases and Vaccinology, Mahoney and Krattiger also serve as advisors to the Rockefeller Foundation. The Foundation asked Mahoney to help organize an international meeting to address how disadvantaged countries could better foster scientific and technology innovation to directly impact health issues. Conducted in Bellagio, Italy in April, the meeting led to development of the Science article.

Participants concluded that the best approach for developing countries may be to pool their resources through "health innovation networks." By working together, the poorest countries stand a better chance of fostering innovation and building economic strength.

The recommended approach sets a top priority of developing public-private partnerships to address these needs. The group suggests that harmonized development in each of six sectors is essential to success in developing innovation systems: manufacturing, domestic markets, export markets, research and development (R&D), intellectual property (IP) systems, and drug regulatory systems.

Mahoney and Krattiger have expertise in one of these crucial aspects: intellectual property (IP).

"Innovation has to include strong public-private collaboration with a clear understanding of the comparative advantages of each sector," said Mahoney. "The big question regarding IP is: How can the public sector better manage IP to help ensure affordable medicines for the poor in developing countries?"

One important component, they say, is improving the linkages between developing and developed countries. Recognizing that global health is critical from both a humanitarian and pragmatic standpoint, philanthropic and government agencies are stepping up to the plate, donating more than $1 billion by 2003 in global product develop partnerships (PDPs) for new drugs, vaccines and diagnostics for diseases of the poor.

Another promising sign is the success being realized by some countries, despite both their relatively low economic strength and per capita income when compared to the U.S., Japan and Europe. These "rising stars" are called innovative developing countries, or IDCs, where recent and rapid increases in R&D investments, longer-term investments in science and engineering education, and increased manufacturing capacity are leading to favorable trends in patents and research citations.

For example, thanks to major investments, China is now the leading manufacturer of penicillin and India, by volume, is now the fourth largest producer of pharmaceuticals in the world.

In fact, the pooled national health research assets of IDCs including Argentina, Brazil, Cuba, China, Indonesia, Malaysia, Mexico, South Africa and Thailand were a combined $2.3 billion in 1998 compared to the U.S. National Institutes of Health’s $13.6 billion.

While this is a step in the right direction, Mahoney and Krattiger point out a major concern. Companies within IDCs are growing rapidly, but all are being driven to maximize a direct economic return of investment, rather than the specific health needs of their populations. As a result, the poor in these countries are not yet benefiting from the new science practiced in their own countries.

"We don’t believe that economic development and addressing national health needs must be mutually exclusive," said Krattiger "There are tensions between the two, but the group concurred that the two are reconcilable."

Several networks have already been formed to leverage the capabilities of these IDCs in ways that benefit a country’s public health and economy. The Developing Country Vaccine Manufacturers’ Network, formed in November 2000, includes state and private owned producers involving Brazil, Cuba, China, India, Indonesia, and Mexico who can sell products through the World Health Organization (WHO) to United Nations agencies. Additional R&D efforts and regulatory networks have followed suit.

Brazil’s human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) program is one of the standout successes of such an approach, with a local manufacturing base to produce antiretroviral drugs combined with a government financing program to provide free access to all who need the drugs.

IDCs can also mimic wealthier countries’ efforts to increase the number of public-private partnerships by providing catalysts for university discovery. For U.S. IP development, the Bayh-Dole Act of 1980 has had an enormously positive impact on technology transfer by universities. This single piece of legislation allowed universities to license more than 3,000 patents, which translated into $40 billion worth of new products and 270,000 jobs created since 2000.

Whether or not something similar to the Bayh-Dole act will work in developing countries is the subject of some debate. "Smaller countries seem to think it can’t work because of the expense of maintaining technology transfer offices in each university," said Mahoney, "but larger countries, e.g. India, seem to think it can work. Korea adopted a Bayh-Dole type of policy some time ago and it seems to work quite well."

In 1954, Korea was one of the two poorest countries in the world. Now, Korea is a high middle-income country with membership in OECD (Organization for Economic Cooperation and Development) and a per capita gross domestic product exceeding $10,000.

Krattiger added that "Whether or not Bayh-Dole type of legislation should be introduced in developing countries misses the key point. The real issue is whether public sector institutions can own inventions, whether they have the freedom to make informed decisions, and whether market type considerations can be allowed to play. That’s what Bayh-Dole really introduced in the U.S. and it has done wonders."

Many of the group’s proposals will require future study, yet there is reason for optimism, as one trend that will continue to grow unabated is the increased connectivity of the world. "In the long term, there will be a global pharmaceutical industry that is extraordinarily more efficient in innovation than it is now and developing countries will be much more effective in innovating to meet the needs of their populations including the poor," said Mahoney.

Joe Caspermeyer | EurekAlert!
Further information:
http://www.asu.edu
http://www.mihr.org
http://www.biodevelopments.org/innovation/index.htm

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>